Zabofloxacin - Dong Wha Pharmaceutical
Alternative Names: DW-224a; DW224aa; PB-101; Zabofloxacin hydrochloride; Zabolante; ZrumgilLatest Information Update: 01 Aug 2019
At a glance
- Originator Dong Wha
- Developer Dong Wha Pharmaceutical; IASO Pharma
- Class Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Naphthyridines; Small molecules
- Mechanism of Action DNA topoisomerase IV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Respiratory tract infections
- No development reported Community-acquired pneumonia
Most Recent Events
- 01 Aug 2019 Phase III development for Respiratory tract infections is ongoing in South Korea (Dong Wha Pharmaceutical, pipeline August 2019)
- 09 Sep 2015 No recent reports on development identified - Phase-II for Community-acquired pneumonia in South Korea (PO, capsule)
- 01 Aug 2014 Dong Wha completes a phase III trial in Respiratory tract infections in South Korea (NCT01658020) (PO, tablet)